molecular profiling
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
PierianDx, Pillar Biosciences Partner to Streamline NGS Cancer Analysis
PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.
John Theurer Cancer Center, Genomic Testing Cooperative to Establish NGS Lab for Cancers
JTCC will adapt validated tests developed by GTC for DNA and RNA profiling of all cancers in its patients with solid tumors of blood cancers.
HTG Molecular Diagnostics Revenues Grow 15 Percent; Firm Lowers Full-Year Guidance
HTG terminated a companion diagnostic development deal with Qiagen in the wake of that company's discontinuation of next-generation sequencing instruments.
Jul 30, 2019